ArticleFrontiers in cardiovascular medicine2020
Current Devices in TMVI and Their Limitations: Focus on Tendyne.
Article in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Morphological Variation in the Human Mitral Valve Using Statistical Shape Modelling.Annals of biomedical engineering · 2026Article
- Technologies in minimally invasive treatment of severe mitral regurgitation.Cardiology journal · 2026Review
- Transcatheter mitral and tricuspid therapy: outcomes in female patients.Indian journal of thoracic and cardiovascular surgery · 2026Review
- Open Heart Mitral Valve Replacement Using Transcatheter Heart Valves for Severe Mitral Annular Calcification-A Literature Review.Journal of cardiovascular development and disease · 2025Review
- Transesophageal Echocardiography in Transcatheter Mitral Valve Replacement.Journal of clinical medicine · 2025Review
- A Novel Self-Expanding Transcatheter Mitral Valve with Dual Annulus/Valve Diameter.Journal of functional biomaterials · 2025Article
- Transcatheter mitral valve implantation using TENDYNE valve for the treatment of residual severe mitral regurgitation post-transcatheter mitral valve edge-to-edge repair: a case report.European heart journal. Case reports · 2024Article
- Massive Superinfected Thrombosis of Dual-Frame Transcatheter Mitral Valve Replacement.JACC. Case reports · 2024Article
- Transcatheter mitral valve replacement - a new option for a selected group of patients?Cardiology journal · 2024Review
- Spontaneously Resolved Systolic Anterior Motion of Native Mitral Valve Leaflet After Transcatheter Mitral Valve Replacement.JACC. Case reports · 2023Article
- Contemporary Review of Transcatheter Mitral Valve Interventions for Mitral Regurgitation.Life (Basel, Switzerland) · 2023Review
- Contemporary treatment of mitral valve disease with transcatheter mitral valve implantation.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- The frail patient undergoing cardiac surgery: lessons learned and future perspectives.Frontiers in cardiovascular medicine · 2023Review
- Outcomes after Transcatheter Mitral Valve Implantation: A Literature Review.Journal of personalized medicine · 2022Review
- Towards the Design and Development of a Robotic Transcatheter Delivery System for Mitral Valve Implant.IEEE transactions on medical robotics and bionics · 2022Article
- Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification.JTCVS techniques · 2021Article
- The 10 Commandments for Transapical TAVI.Innovations (Philadelphia, Pa.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral valve regurgitation (MR) has a high incidence in the western world, and mortality is high for untreated severe MR. Catheter based repair was introduced with MitraClip in 2003, and some additional devices later came into the market. To expand the transcatheter treatment options for mitral valve disease, the first transcatheter mitral valve implantation (TMVI) was performed by Søndergaard et al. 2012, only 10 years after the first transcatheter aortic valve implantation (TAVI), however, the development has been much slower for the TMVI than for TAVI. From 2012, studies were started for several devices to prove feasibility and safety. However, there were big challenges in valve design; delivery systems and anchoring in addition to anatomical issues (avoid LVOT obstruction and paravalvular leak, big size of annulus). The main valves in studies were CardiaQ (later bought by Edwards Lifesciences, Irvine, United States), Tiara (Neovasc Inc., Richmond, Canada), Twelve (later Intrepid, Medtronic, MN, United States) and Tendyne™ (Abbott, MN, United States). I will focus on the Tendyne™ valve that is the only CE approved transcatheter mitral valve implant. It is available in a large number of sizes and is repositionable and retrievable. The results for the 100 first patients included in the early feasibility study (EFS) at 1 and 2 years are promising. Initially feasible for MR, but further investigations show promising results also for implant in mitral annular calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.